46K Stock Chart & Stats
€74.50
€0.00(0.00%)
At close: 4:00 PM EDT
€74.50
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€58.00 - €89.50
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€962.77M
Enterprise Value€1.17K
Total Cash (Recent Filing)€59.08M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)47.1
Beta0.27
Next Earnings
Oct 29, 2026EPS Estimate
0.48Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.82
Shares Outstanding12,786,991
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio3.34
Price to Book (P/B)13.08
Price to Sales (P/S)14.77
P/FCF Ratio72.03
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€104.68Price Target Upside40.51% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)1.83
Revenue Forecast (FY)€79.73M
Bulls Say, Bears Say
Bulls Say
High And Consistent ProfitabilityVery high gross and net margins indicate strong earnings power in IRMD’s specialized medical-device model. Their historical consistency provides a durable buffer for research, service investment, and commercial expansion, while supporting resilient profitability over the next several quarters.
Debt-free Balance SheetAn essentially debt-free balance sheet materially lowers financial risk and preserves flexibility during product transitions or periods of uneven demand. IRMD can deploy internally generated resources toward growth and operations without substantial interest or refinancing burdens.
Strong Product Demand And Higher-value MixDemand exceeding shipments suggests a meaningful order backlog, while adoption of four-channel systems increases revenue per replacement. This mix shift can support durable growth and strengthen the commercial value of IRMD’s MRI-compatible pump franchise as customers upgrade.
Bears Say
Moderating Revenue MomentumTop-line momentum has slowed from the stronger growth reported in earlier years, and nearly flat quarterly revenue indicates limited near-term acceleration. Persistent moderation could constrain operating leverage and make future earnings growth more dependent on successful product adoption.
Ramp-related Margin And Execution PressureThe 3870 launch is temporarily reducing manufacturing efficiency and gross margin, creating execution risk while production scales. If expected cost reductions and learning-curve benefits are delayed, elevated labor and overhead could continue weighing on profitability through the next few quarters.
3860-to-3870 Transition RiskMoving customers from the legacy 3860 platform to the 3870 can create timing and service complexity across the installed base. Longer lead times and disruption to attached disposables may pressure revenue timing and recurring sales until the transition becomes more established.
Iradimed News
46K FAQ
What was Iradimed Corp’s price range in the past 12 months?
Iradimed Corp lowest stock price was €58.00 and its highest was €89.50 in the past 12 months.
What is Iradimed Corp’s market cap?
Iradimed Corp’s market cap is €962.77M.
When is Iradimed Corp’s upcoming earnings report date?
Iradimed Corp’s upcoming earnings report date is Oct 29, 2026 which is in 31 days.
How were Iradimed Corp’s earnings last quarter?
Iradimed Corp released its earnings results on Jul 31, 2026. The company reported €0.401 earnings per share for the quarter, beating the consensus estimate of €0.384 by €0.017.
Is Iradimed Corp overvalued?
According to Wall Street analysts Iradimed Corp’s price is currently Undervalued.
Does Iradimed Corp pay dividends?
Iradimed Corp does not currently pay dividends.
What is Iradimed Corp’s EPS estimate?
Iradimed Corp’s EPS estimate is 0.48.
How many shares outstanding does Iradimed Corp have?
Iradimed Corp has 12,786,991 shares outstanding.
What happened to Iradimed Corp’s price movement after its last earnings report?
Iradimed Corp reported an EPS of €0.401 in its last earnings report, beating expectations of €0.384. Following the earnings report the stock price went up 0.614%.
Which hedge fund is a major shareholder of Iradimed Corp?
Currently, no hedge funds are holding shares in DE:46K
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Iradimed Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€104.68 (40.51% Upside)
€104.68 (40.51% Upside)
Blogger Sentiment
Bearish
DE:46K Sentiment 100%
Sector Average 64%
Sector Average 64%
Insider Transactions
Sold Shares
Worth €107.7K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
26.83%
12-Months-Change
Fundamentals
Return on Equity
1.46%
Trailing 12-Months
Asset Growth
8.01%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Iradimed Corp
IRADIMED CORPORATION specializes in the engineering, production, and distribution of medical devices specifically designed for compatibility with magnetic resonance imaging (MRI) environments. The company supplies these specialized products, alongside their related accessories and support services, to both U.S. and international markets. Key offerings include the MRidium MRI-compatible intravenous (IV) infusion pump system, which comes with disposable tubing sets, and an MRI-compatible patient vital signs monitoring system. Furthermore, IRADIMED provides a range of complementary items such as non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring solutions with sensors. Their clientele primarily consists of hospitals, acute care facilities, and outpatient imaging centers. Sales are conducted via direct field representatives, regional sales directors, clinical support specialists, and independent distributors. Founded in 1992, IRADIMED CORPORATION is headquartered in Winter Springs, Florida.
46K Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a largely positive outlook driven by a successful product launch (3870 pump), strong bookings (bookings >2x units shipped), higher ASPs from quad replacements, record monitor orders, and improving recurring revenue and cash flows. Near-term challenges include margin compression and higher costs from the initial production ramp, a modest decline in quarterly net income and gross margin, and an elevated effective tax rate. Management provided clear plans and guidance to double down on ramp execution, expects significant cost reductions in Q3 and near-historic efficiencies by Q4, and reaffirmed full-year guidance — resulting in confidence that the positive drivers outweigh the near-term operational headwinds.View all DE:46K earnings summaries46K Stock 12 Month Forecast
Average Price Target
€104.68
▲(40.51% Upside)